Indication
HEPCVIR-L is used for the treatment of chronic hepatitis C virus (HCV).
Note
Precaution
HEPCVIR-L is a prescription drug and should be used under proper medical guidance and advice.
Hepcvir-l (90 mg Ledipasvir /400 mg Sofosbuvir)
| CIPLA LTD. |
HEPCVIR-L is a fixed-dose combination of “LEDIPASVIR AND SOFOSBUVIR” which are direct acting antiviral agents against the hepatitis C virus (HCV). Ledipasvir is an inhibitor of the protein, which is required for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate which can be incorporated into HCV RNA and acts as a chain terminator.
